Edward Kai-Hua CHOW
The Chow laboratory seeks to improve cancer therapy, especially in the context of combination therapy, through multidisciplinary methods that include engineering-based approach, such as AI, nanotechnology and automated laboratory systems. We are particularly interested in how to quickly and accurately identify effective cancer therapeutic options for individual cancer patients as well as specific sub-groups of cancer patients in both blood cancers and solid tumors. Additionally, we seek to understand how the molecular mechanisms behind why specific patients or groups of patients respond to specific therapies and how this can be applied towards broader cancer populations.
csikce[at]nus.edu.sg
Principal Investigator, Cancer Science Institute of Singapore, NUS
NUS Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, NUS
The Chow laboratory is interested in a developing a comprehensive translational approach to understanding and treating cancer. Through the incorporation of AI, nanotechnology, automated combinatorial drug screening and biochemistry, improved cancer therapy approaches as well as the molecule mechanisms that underpin their efficacy can be quickly developed. We are particularly interested in using technology to develop truly personalised medical approaches that can identify the best therapeutic options for individual patients. While providing valuable insight into effective therapies for specific patients, this data is also used to identify critical molecular mechanisms of cancer pathogenesis that are worth further interrogation. While we are interested in a wide range of cancers, much of this progress has been made primarily in lymphomas, myeloma and gastrointestinal cancers. Beyond demonstrating that personalised medicine is possible in these cancers, we are focused on understanding the molecular mechanisms by which epigenetics affects these cancers as a number of novel effective epigenetic-based combinations have been identified across a wide range of patient samples. Understanding the mechanisms that underpin the efficacy of epigenetic-based therapy in individual patient samples will allow us to provide greater scientific rationale towards application of epigenetic-based combinations across a broader range of cancer patients as well as improve epigenetic drug development.
Lab Members
